The intersection of healthcare and technology is reaching a critical inflection point as health insurance companies increasingly turn to artificial intelligence to manage patient care. Whereas the promise of efficiency is high, the shift toward using AI to make coverage decisions is raising significant concerns among medical professionals and patient advocates regarding the potential for systemic risks to patient safety.
Industry executives have signaled to Wall Street analysts that integrating AI into coverage decisions is a primary strategy for reducing costs. This transition is not limited to private insurers; the Trump administration is reportedly testing the utility of AI in managing the prior authorization process for the Medicare program, indicating a broader push toward automated healthcare administration.
As an internist and journalist, I have seen how administrative hurdles can delay critical interventions. When these hurdles are managed by algorithms rather than clinicians, the risk of “algorithmic denial”—where a patient is denied a necessary treatment based on a data-driven pattern rather than a clinical reality—becomes a pressing public health concern.
The stakes are particularly high for the millions of seniors relying on federal programs. Recent reports indicate that the Trump administration intends to raise 2027 Medicare Advantage payments by 2.48%, a figure that exceeds some analysts’ expectations according to the Wall Street Journal. With higher payments and a push toward AI-driven cost-cutting, the balance between insurer profitability and patient care is under intense scrutiny.
The Mechanics of AI in Coverage Decisions
At the heart of this shift is the “prior authorization” process—the requirement that a healthcare provider obtain approval from an insurance company before a specific service, medication, or piece of medical equipment is delivered. Traditionally, this involved a review by a medical director or a nurse. Now, AI tools are being deployed to analyze patient records and determine if a requested treatment meets the insurer’s specific criteria.
The appeal for insurers is clear: AI can process thousands of requests in seconds, identifying patterns that suggest a treatment may be unnecessary or that a cheaper alternative should be tried first. However, the risk lies in the “black box” nature of these algorithms. If an AI denies a claim based on a flawed data set or a rigid interpretation of guidelines, the patient may face delays in receiving life-saving care.
This automation is coinciding with a period of significant volatility in how Medicare Advantage is managed. We find ongoing reports that the Trump administration is considering the automatic enrollment of seniors into Medicare Advantage plans as detailed in a Wall Street Journal opinion piece. If automatic enrollment is paired with AI-driven coverage denials, the impact on the elderly population could be profound.
Financial Incentives and the Risk of Overbilling
The push toward AI efficiency cannot be viewed in a vacuum, separate from the financial structures of the insurance industry. There is a documented history of tension between the reporting of patient health status and the payments received by insurers.
A rigorous investigation by the Wall Street Journal newsroom, which analyzed 1.6 billion Medicare Advantage records over 12 years, revealed a systemic issue with “upcoding.” The investigation found that between 2018 and 2021, Medicare Advantage plans received approximately $50 billion in payments for diagnoses that were questionable—conditions added to records by insurers rather than by the treating physicians according to an analysis by Wendell Potter.
When AI is introduced into this environment, there is a risk that the technology will be optimized not for patient health, but for financial gain. If an algorithm is designed to maximize “risk adjustment” payments while simultaneously minimizing the cost of care through automated denials, the patient becomes a variable in a profit-maximization equation rather than a recipient of medical care.
Who Is Affected and What It Means for Patients
The transition to AI-led coverage decisions affects several key stakeholders in the healthcare ecosystem:
- Patients: The primary risk is the delay or denial of necessary care. When AI overrides a doctor’s recommendation, patients often face a bureaucratic appeal process that can take weeks, during which their condition may worsen.
- Physicians: Doctors are finding themselves in increasing conflict with “algorithmic medicine.” The time spent fighting AI-generated denials reduces the time available for direct patient care.
- Regulators: Agencies like the Centers for Medicare and Medicaid Services (CMS) must now determine how to oversee algorithms that are proprietary and often opaque.
The “what it means” for the average patient is a shift in the locus of control. Medical decisions are moving away from the bedside—where the physician and patient collaborate—and toward a data center where an algorithm determines the “cost-effectiveness” of a treatment.
The Path Forward: Accountability and Oversight
As the Trump administration continues to test AI’s usefulness in the Medicare program, the call for transparency is growing. For AI to be a tool for improvement rather than a tool for denial, several safeguards are necessary:
First, there must be a “human-in-the-loop” requirement. An AI should be able to suggest a denial, but a licensed clinician must review and sign off on that decision, ensuring that the individual patient’s nuances are considered.
Second, there must be transparency regarding the data used to train these models. If an AI is trained on data that reflects historical biases or focuses solely on cost-reduction, the output will inevitably be skewed toward denial.
Finally, there must be a mechanism for rapid appeal. If an AI denies a critical treatment, the appeal process should not be a slow, manual slog, but a streamlined path to a human medical review.
Key Takeaways on AI in Healthcare Coverage
| Area of Impact | Current Trend | Primary Risk |
|---|---|---|
| Prior Authorization | Shift toward AI-driven approvals | Delayed or denied critical care |
| Medicare Advantage | Increased payments (2.48% in 2027) | Focus on profit over patient outcomes |
| Financial Reporting | History of $50B in questionable payments | AI optimizing for “upcoding” rather than health |
| Patient Enrollment | Considering automatic enrollment | Reduced patient choice in care models |
The trajectory of healthcare AI is currently being shaped by the pursuit of cost-savings. However, the true measure of success for any medical technology is not the amount of money saved by an insurer, but the improvement in patient outcomes. As we move toward 2027, the tension between the financial goals of the insurance industry and the clinical needs of patients will likely define the next era of public health policy.
The next critical checkpoint will be the official implementation of the 2027 Medicare Advantage payment rates and any formal announcements from the Trump administration regarding the rollout of AI in the prior authorization process.
Do you believe AI should have a role in deciding your medical coverage? We invite you to share your thoughts and experiences in the comments below.
- Diabetic Neuropathy: Causes, Symptoms, and Effective Treatment Options
- FDA Approves Bizengri (zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma
- UAMS and Mena Regional Health System Announce Strategic Partnership (news-usa.today)
- Insurance Rates Decline Despite Rising Loss Frequencies (archyde.com)